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Exaggerated QT Prolongation
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OBJECTIVES The purpose of this study was to test the hypothesis that the extent of drug-induced QT
prolongation by dofetilide is greater in sinus rhythm (SR) after cardioversion compared with
during atrial fibrillation (AF).
BACKGROUND Anecdotes suggest that when action potential–prolonging antiarrhythmic drugs are used for
AF, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinus
rhythm is restored.
METHODS QT was measured in nine patients with AF who received two identical infusions of dofetilide:
1) before elective direct current cardioversion and 2) within 24 h of restoration of SR.
RESULTS During AF, dofetilide did not prolong QT (baseline: 368 6 48 ms vs. drug: 391 6 60, p 5
NS) whereas during SR, QT was prolonged from 405 6 55 to 470 6 67 ms (p , 0.01). In
four patients (group I), the SR dofetilide infusion was terminated early because QT prolonged
to .500 ms, and one patient developed asymptomatic nonsustained TdP. The remaining five
patients (group II) received the entire dose during SR. Although DQT was greater in group
I during SR (91 6 22 vs. 45 6 25 ms, p , 0.05), plasma dofetilide concentrations during SR
were similar in the two groups (2.72 6 0.96 vs. 2.77 6 0.25 ng/ml), and in AF (2.76 6 1.22
ng/ml). DQT in SR correlated inversely with baseline SR heart rate (r 5 20.69, p , 0.05),
and QT dispersion developing during the infusion (r 5 0.79, p , 0.01).
CONCLUSIONS Shortly after restoration of SR, there was increased sensitivity to QT prolongation by this
IKr-specific blocker. Slower heart rates after cardioversion and QT dispersion during
treatment appear to be important predictors of this response. (J Am Coll Cardiol 1999;34:
396–401) © 1999 by the American College of Cardiology
Although drugs that prolong the QT interval can suppress
arrhythmias, their potential to cause excessive QT prolon-
gation, leading to the development of the polymorphic
ventricular tachycardia torsades de pointes (TdP), is well
recognized. When such agents are used to treat atrial
fibrillation (AF) or flutter, clinical anecdotes suggest that
TdP occurs more frequently after conversion to sinus
rhythm (SR) rather than during the atrial arrhythmia (1–4).
The purpose of this study was to prospectively test the
hypothesis that an action potential–prolonging antiarrhyth-
mic drug would exert a greater effect on cardiac repolariza-
tion (as measured by the QT interval) shortly after restora-
tion to SR compared with during AF or atrial flutter. Most
QT-prolonging drugs (quinidine, sotalol, disopyramide,
amiodarone) exert ancillary pharmacologic effects (e.g.,
autonomic blockade) that might confound testing of this
hypothesis. Therefore, in this study, we used dofetilide,
which exerts repolarization-prolonging effects due to block
of the rapidly activating, outward potassium current, IKr
(5,6). Dofetilide, which is devoid of significant other phar-
macologic effects, prolongs refractoriness in most tissues,
and its sole electrocardiographic (ECG) effect is QT pro-
longation (7,8). The efficacy of dofetilide in the acute
cardioversion of AF or atrial flutter has been previously
reported (9). The goal of the present study was to use the
drug to determine whether the extent of QT interval change
depended on whether the rhythm was AF or sinus and, if
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there was a difference, what the underlying mechanism(s)
might be.
METHODS
Participants. Twelve patients (nine male, three female)
with AF (n 5 9) or atrial flutter (n 5 3) scheduled for
elective direct current cardioversion were recruited consec-
utively from the Arrhythmia Service at Vanderbilt Univer-
sity Medical Center. All participants had a history of
hypertension. Coronary artery disease was present in four,
and diabetes in four. All participants provided written
informed consent, and the study was approved by the
Vanderbilt University Institutional Review Board.
Patients were enrolled into the study if they met the
following eligibility criteria: AF or atrial flutter of more than
24 h but less than 12 months duration in whom elective
direct current cardioversion was planned; therapeutic anti-
coagulation for at least two weeks before study entry, unless
the arrhythmia was atrial flutter; normal biochemical and
hematologic parameters and no symptoms of unstable an-
gina or decompensated congestive heart failure. Women of
childbearing potential and patients with previous adverse
reactions to QT-prolonging drugs were excluded. All pa-
tients had a full medical history, physical examination,
urinalysis, 12-lead ECG, biochemistry and hematologic
examination before entry into the study. Patients were
admitted to the Clinical Research Center at Vanderbilt
University for continuous monitoring of cardiac rhythm
while all antiarrhythmic therapy was stopped 48 h before
the study. Because dietary sodium can influence atrial
natriuretic peptide (ANP) release (10) and QT interval (11),
a sodium-controlled diet was given to all subjects during this
period and for the duration of the study. Oral digoxin was
used for rate control if required, and other atrioventricular
nodal blocking agents were withheld for .24 h before entry
to the study.
Protocol. Each patient was scheduled to received two
infusions of dofetilide, each after a 6- to 8-h overnight fast:
the first infusion during AF and the second during SR,
within 24 h of cardioversion. If the AF infusion did not
restore SR, scheduled cardioversion was performed the same
day. On the morning of each study day, an intravenous line
was inserted in each arm of the supine patient, one for drug
administration and the other for blood sampling of plasma
drug concentrations; serum potassium and magnesium and
plasma ANP and norepinephrine.
Intravenous dofetilide (Pfizer, Groton, Connecticut) was
administered in a three-stage infusion over 100 min. The
first six patients received 5.25 mg/kg over 100 min: 0.198
mg/kg/min for 5 min, 0.065 mg/kg/min for 35 minutes,
then 0.033 mg/kg/min for 60 min. In the next six patients,
the dose was 8 mg/kg over 100 min, and the rates of the
three infusions were 0.3, 0.1 and 0.05 mg/kg/min, with the
same infusion durations. Each patient received the same
infusions on both study days. Infusion rates were based on
pharmacokinetic data describing the disposition kinetics of
dofetilide boluses in human participants and were designed
as previously described (8,12) to rapidly achieve and then
maintain stable plasma concentrations in the 1.5- to 2.5-
ng/ml range. Electrocardiograms were recorded at baseline
and every 10 min during the infusion.
Blood sampling and assays. Venous samples were col-
lected at baseline (5 min before dofetilide infusion) for
serum potassium and magnesium, plasma norepinephrine
and plasma ANP. Serum potassium and magnesium and
plasma norepinephrine were analyzed by Roche Biomedical
Laboratories (Newark, New Jersey) and LabCorp (Burling-
ton, North Carolina), respectively. Samples for measure-
ment of plasma dofetilide were collected at baseline and at
specified time points during infusion, and were analyzed by
high pressure liquid chromatography (Pfizer Central Re-
search, Groton, Connecticut). Plasma ANP was measured
by radioimmunoassay as previously described (13) (AD
Struthers, University of Dundee Medical School, U.K.).
QT analysis. All ECGs were recorded with the patient
resting supine, using an analog system at 25-mm/s paper
speed, 10-mm/mV gain and 40-Hz low pass filter setting.
The ECGs were analyzed using a semiautomated digitizing
program by a single observer. Intraobserver variability was
examined by randomly selecting 50 ECGs to be reanalyzed
by the same observer; the coefficient of variation was 4% to
6%. To examine for interobserver variability, independent
duplicate determinations were made by a second blinded
observer; the coefficient of variation between patients was
8% to 10%. The QT interval was measured in a precordial
lead (V2 or V3) from the onset of the QRS to the end of the
T wave, as extrapolated from the maximum negative slope
of the T wave to the baseline. During both AF and SR, in
the presence of a U wave greater than 25% of the amplitude
of the T wave, the QTU interval was similarly measured. In
each patient, the same precordial lead was measured in AF
and SR. The mean of five consecutive QT intervals mea-
sured in AF and SR was used. The limb leads were not used
in this analysis because when the underlying rhythm was
AF, it was not possible to distinguish low amplitude U
waves from coarse fibrillatory activity in the limb leads.
Similarly, since U waves tend to occur in some leads and not
others, DQT (the change in QT) was not measured in a
single lead, but rather QT in all precordial leads was
Abbreviations and Acronyms
AF 5 atrial fibrillation
ANP 5 atrial natriuretic peptide
ECG 5 electrocardiographic/electrocardiogram
QTd 5 QT dispersion
SR 5 sinus rhythm
TdP 5 torsades de pointes
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measured, and the mean of the differences in each lead was
used to calculate DQT.
Dispersion of the QT interval (QTd) during SR was
calculated as the difference between maximal and minimal
QT intervals occurring in any of the 12 leads, and adjusted
using the formula QTd 5 (maximum QT 2 minimum
QT)/Ö (number of leads measured) (14). For the reasons
outlined above, QTd was not measurable when the under-
lying rhythm was AF. Mean heart rate was calculated in
both AF and SR from five consecutive complexes.
Analysis of the difference in QT and heart rate before and
after infusion during AF and during SR was performed by
using analysis of variance with repeated measures. Differ-
ences in DQT in all patients and by subgroup were tested
using the paired and unpaired Student t test where appro-
priate. All tests were two tailed, and a p value of ,0.05 was
considered to be significant. All data are presented as
mean 6 1 SD.
RESULTS
Twelve patients participated in the study, three women and
nine men. One patient cardioverted from atrial flutter to SR
after 60 min of infusion. The remaining 11 patients received
the entire 100-min infusion of dofetilide during AF without
cardioversion to SR. After dofetilide infusion, three patients
did not electrically cardiovert and were withdrawn from the
study.
All of the remaining nine patients received the second
infusion during SR. In four patients, the infusion was
terminated early (2 after 20 min, 1 after 30 min and 1 after
60 min) because of QT prolongation to more 500 ms in at
least two ECG leads. One of these participants developed
asymptomatic, recurrent runs of TdP self-terminating after
up to 17 beats and lasting over 10 min after stopping the
infusion. The remaining patients (group II) completed the
second infusion. The mean time from cardioversion to SR
infusion was 19 6 2 h. There was no relationship between
the time between cardioversion and the outcome of the SR
study.
Three patients in group I and two patients in group II
received the higher dose of dofetilide. There were no
significant differences in the clinical or demographic char-
acteristics between group I and group II, and the durations
of AF and previous treatments were similar. No other
adverse effects and no significant changes occurred in
systolic and diastolic blood pressure during the infusion in
both AF and SR.
QT intervals. Data are presented in Figure 1 for the first
100 min of the infusion during both AF and SR. In group
I, data for the first 20 min are shown, as this was the time
point that all four patients reached in SR. Baseline QT in
AF and SR was not significantly different (AF vs. SR:
386 6 49 and 420 6 39 ms, p 5 NS). There was minor QT
prolongation with dofetilide during AF, but the change was
not significant (baseline and 100 min infusion: 386 6 49
and 420 6 60 ms, p 5 NS). The increment in QT produced
by dofetilide infusion during SR in group II was similar to
that seen in AF (412 6 52 ms at baseline vs. 459 6 62 ms
at end-infusion, p 5 NS). In contrast, in group I, dofetilide
administered during SR increased QT from 432 6 15 to
580 6 63 ms after 20 min infusion (p , 0.01 baseline vs.
20 min).
Other differences—AF versus SR. Despite the signifi-
cantly different QT responses during AF and SR, plasma
dofetilide concentrations were comparable on the two study
days (Fig. 1). Baseline heart rate in AF (81 6 17 beats/min)
was higher than in SR (68 6 15 bpm), although this was not
statistically significant. Dofetilide infusion did not signifi-
cantly alter heart rate in either AF or SR (Fig. 1).
There was no significant difference in mean serum po-
tassium before infusion during AF and SR (4.3 6 0.1
mEq/liter and 4.1 6 0.1 mEq/liter, respectively). Mean
serum magnesium was normal in all patients before infusion
in AF and SR. Atrial natriuretic peptide during AF was
elevated, 167 6 89 pg/ml (normal range 7.3 to 32.4 pg/ml)
Figure 1. Precordial QT (top), heart rate (middle) and plasma
dofetilide (bottom) during dofetilide infusion in atrial fibrillation
or flutter and after cardioversion to normal sinus rhythm (SR).
Group I patients are those in whom the SR infusion was stopped
prematurely for excess QT prolongation. Group II patients re-
ceived the whole dofetilide infusion in SR. *p , 0.01 vs baseline.
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and fell after cardioversion to 71 6 46 pg/ml (p 5 0.04).
Plasma norepinephrine fell after cardioversion from 127 6
47 pg/ml to 91 6 59 pg/ml (p 5 NS).
Differences between groups I and II. Whereas there was
no significant difference in QT at baseline (431 6 14 vs.
411 6 52) between the two groups, QT at 10 and 20 min
of the SR infusion was significantly longer in group I than
in group II (10 min: 585 6 80 vs. 443 6 71 ms; 20 min:
580 6 63 vs. 432 6 27 ms both, p , 0.05). Thus, DQT was
significantly greater in group I compared with group II
(91 6 22 vs. 45 6 25 ms, p , 0.05). Group I tended to have
slower heart rates compared with group II (62 6 17 vs. 74 6
13 bpm), although this difference was not statistically
significant. There was a significant correlation between
baseline heart rate and DQT (r 5 20.69, p , 0.05).
QT dispersion. QT dispersion during SR increased with
dofetilide infusion from 30 6 6 ms at baseline to 42 6
15 ms at 20 min, but this change was not statistically
significant. However, QTd measured at 20 min of infusion
correlated significantly with DQT (r 5 0.79, p 5 0.01). The
correlation was similar when QTd was calculated without
correction for the number of leads measurable (r 5 0.76,
p 5 0.019). Again, QTd tended to be greater in group I
patients compared with group II patients (49 6 15 vs. 38 6
8 ms, p 5 NS).
DISCUSSION
The major finding of this study is that there is increased
sensitivity to the QT-prolonging effects of dofetilide in
some patients after restoration of SR compared with during
AF. This exaggerated QT response was not seen during AF
at comparable plasma drug concentrations in the same
patients. Slower heart rates postcardioversion and increasing
QT dispersion during dofetilide infusion were associated
with exaggerated QT response, but no other clinical or
demographic characteristic identifying patients at risk was
identified. Serum potassium, which we have previously
shown to be an important modulator of drug-induced QT
prolongation (15), was not significantly different during AF
and SR, or between the two groups during SR, and
therefore does not appear to modulate this differential QT
response to dofetilide.
Only one of the 12 patients in this study was cardioverted
by intravenous dofetilide, whereas previous studies report
conversion to sinus rhythm by intravenous dofetilide in 15%
to 58% (9,16,17) of patients with AF and 54% to 83% (9,17)
of those with atrial flutter. It is likely that the rate of
infusion accounts for this difference, as animal data indicate
that the rate of infusion is a crucial determinant of the
extent to which pharmacologic effects are observed with an
IKr blocker (18). The total dose of dofetilide used in this
study was comparable to those in previous studies, but the
rate of infusion was lower and was specifically chosen to
study the effects of dofetilide on QT prolongation in the
two rhythms, rather than to achieve pharmacologic cardio-
version.
The QT intervals in this study are presented uncorrected
for heart rate. The relationship of QT to heart rate in AF
appears to be different from that in SR (19) and correction
by Bazett’s formula (20) appears to undercorrect the QT. In
addition, correction of the QT interval by Bazett’s formula
would have been inappropriate at the very slow or fast heart
rates seen in some of our patients (21). However, it has been
reported that under conditions of rest versus exercise, the
relationship of the QT interval to heart rate is less strongly
correlated, and QT interval is relatively unchanged with
regard to heart rate (22).
Mechanism of increased QT sensitivity. The finding of a
correlation between heart rate and the extent of change in
QT may be a manifestation of the property of reverse
use-dependence displayed by many action potential–
prolonging antiarrhythmics (23). However, this character-
istic is not likely to explain the near-total lack of QT change
in AF (or in group II), in the face of a striking increase—at
marginally slower heart rates—in group I. Moreover, some
in vitro and clinical studies have suggested that over this
range of heart rates, dofetilide does not exert prominent
reverse use-dependence (24,25).
Although baseline bradycardia identifies patients at risk
for drug-induced QT prolongation in this and other (26)
studies, we do not believe that the small differences in
baseline heart rates are sufficient to completely explain the
striking QT prolongation we observe in group I. We
therefore suspect that other, as yet unidentified mechanisms
conferred increased risk in this group. One possibility is an
altered neurohormonal milieu, such as changing sympa-
thetic nervous activity (27,28) or ANP levels (29); this could
modulate a change in drug sensitivity by altering the
magnitude of one or more of the multiple currents that
control repolarization (30–32). Another possibility is that
some of these patients had subclinical mutations in the
genes encoding repolarizing channels, as has previously been
reported (33); this could then reduce total “repolarization
reserve” (34), with QT prolongation becoming exaggerated
upon exposure to a blocking drug such as dofetilide.
Study limitations. All the patients in this study had AF
associated with long-standing hypertension, and other car-
diovascular disease was present in most. It remains unde-
termined if increased sensitivity to dofetilide or other drugs
is similarly seen after restoration of SR from lone AF or AF
associated with noncardiovascular disease. The small size of
this study may also represent a limitation, particularly in
interpreting ANP and norepinephrine data. We considered
studying larger numbers, but the development of TdP in
one patient and analysis of available QT data convinced us
that our central hypothesis had been tested. Further studies
will be required to more fully elucidate the suggestions from
our data of a role for ANP, norepinephrine or genetic
factors in mediating the exaggerated QT prolongation seen
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in group I during SR. The Food and Drug Administration’s
Cardiorenal Advisory panel recently recommended approval
for the marketing of oral dofetilide for maintenance of SR
after conversion of AF. The major adverse effect in the
summary data presented was TdP. The incidence in patients
with supraventricular arrhythmias was low, 0.8% (11/
1,346), after maneuvers were implemented to reduce the
risk, including screening patients for excessive QT prolon-
gation and hospitalizing patients during initiation of ther-
apy. Whether other markers implicated here might help
further reduce this risk, or allow out patient drug initiation
in some subsets, will require further study.
The correct method to measure QT interval, especially in
the presence of a U wave, is not established. When the
underlying rhythm was AF, we could not distinguish U
waves from fibrillatory activity, and so we used measurement
of QT only. When an obvious QTU complex developed
during SR, we included the U wave in determining QT and
in the calculation of QT dispersion. Because a goal of this
study was to evaluate susceptibility to TdP, and because
large U waves are common with the development of TdP
(35), we feel this approach is justified here.
Clinical implications. We did not study participants again
days or weeks after SR was restored, so we have no data as
to whether the susceptibility identified here is transient or
remains as long as SR remains. The clinical anecdotes that
in part prompted this study suggest the susceptibility is
transient. In addition, it has been reported that normal
volunteers receiving sotalol (like dofetilide, an IKr blocker
[36]) display greater QT prolongation with initial doses that
with chronic therapy, achieving the same plasma concen-
trations (37). The mechanism(s) underlying this effect are
unknown, but a similar phenomenon could contribute to the
susceptibility we observed here.
From a practical point of view, the present data further
reinforce the concept that patients receiving QT-prolonging
antiarrhythmics for maintenance of SR should be closely
evaluated in the immediate postcardioversion period to
detect excessive QT prolongation. Such monitoring, in our
view, should include assessment, preferably in multiple
leads, by individuals sensitized to issues of QT lability and
of postpause QTU duration and morphology. Our data
indicate that this sensitivity is present for at least 24 h,
although future studies would be required to determine
whether monitoring the QT for a shorter period of time
after cardioversion might be sufficient to detect patients
displaying this exaggerated response. Our data also indicate
that QT dispersion in SR may be a marker of undesirable
QT prolongation.
New class III antiarrhythmic drugs, many of which
include an important component of IKr block (38), appear to
have potential in the treatment of acute and chronic atrial
arrhythmias. The main disadvantage with these otherwise
well tolerated antiarrhythmic agents is their potential to
cause excessive QT prolongation and development of TdP.
Our data suggest that the QT response to one of these
drugs, dofetilide, during AF does not predict the response
after restoration to SR, and that exaggerated QT responses
may occur in predisposed individuals. Monitoring of the
QT interval in all patients after restoration of SR and dose
adjustment may be prudent, particularly in the presence of
bradycardia and increasing QT dispersion during treatment.
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